Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Shuhang Wang"'
Publikováno v:
Lung Cancer. 135:116-122
Objectives The utility of malignant pleural effusion (MPE) as a source for determining EGFR mutations to guide EGFR TKI therapy in advanced adenocarcinoma of the lung remains unclear. This study compared MPE, plasma and tumor tissues as sources of bi
Publikováno v:
Cancer Science
Some driver gene mutations, including epidermal growth factor receptor (EGFR), have been reported to be involved in expression regulation of the immunosuppressive checkpoint protein programmed cell death ligand 1 (PD-L1), but the underlying mechanism
Autor:
Meina Wu, Guanhua Rao, Hua Bai, Yuyan Wang, Fei Gai, Lei Li, Tongtong An, Minglei Zhuo, Shuhang Wang, Zhijie Wang, Wanchun Zang, Jie Wang, Jia Zhong, Jun Zhao, Jianchun Duan, Guanshan Zhu
Publikováno v:
Journal of Thoracic Oncology. 12:1766-1778
Introduction EGFR tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of lung adenocarcinoma. However, approximately 5% to 10% of patients with lung adenocarcinoma with EGFR sensitive mutations have primary resistance to EGFR TKI tr
Autor:
Shuhang Wang, Di Wang, Qingqing Li, Jin Wang, Meina Wu, Minglei Zhuo, Fuchou Tang, Zhijie Wang, Zhenlin Yang, Jie Wang, J. Jack Lee, Tongtong An, Zhaoli Chen, Hua Bai, Jianchun Duan, Jun Zhao, Rui Wan, Yu Sun
Publikováno v:
Journal of Thoracic Oncology. 12:1376-1387
Introduction This study aimed to address the underlying reasons for and clinical significance of the discordant EGFR mutation ( EGFR m) status between tumor tissue (TT) and circulating tumor DNA (ctDNA). Methods Three groups of EGFR tyrosine kinase i
Publikováno v:
Frontiers of Medicine. 10:383-388
The tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are becoming the first line of therapy for advanced non-small cell lung cancer (NSCLC). Acquired mutations in EGFR account for one of the major mechanisms of resistan
Autor:
Jie Wang, Hua Bai, Shuhang Wang, Jianchun Duan, Jun Zhao, Jiang-Yong Yu, Si-Fan Yu, Tongtong An
Publikováno v:
Chinese Journal of Cancer, Vol 35, Iss 1, Pp 1-10 (2016)
Chinese Journal of Cancer
Chinese Journal of Cancer
Background Epidermal growth factor receptor (EGFR) mutations, including a known exon 19 deletion (19 del) and exon 21 L858R point mutation (L858R mutation), are strong predictors of the response to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment
Publikováno v:
Cancer letters. 385
The third-generation tyrosine kinase inhibitors (TKI), AZD9291 (osimertinib) and CO-1686 (rociletinib) of epidermal growth factor receptor (EGFR) are highly active against T790M positive non-small cell lung cancer (NSCLC). However, resistance develop
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-7 (2016)
Journal of Hematology & Oncology, Vol 9, Iss 1, Pp 1-7 (2016)
The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M mutation leads to resistance to most clinically available EGFR TKIs. Third-g
Autor:
Hua Bai, Zhijie Wang, Jianchun Duan, Xiaomei Su, Minglei Zhuo, Tongtong An, Meina Wu, Zhenxiang Li, Shuhang Wang, Jie Wang, Jun Zhao, Jian Zhu
Publikováno v:
Journal of Hematology & Oncology
EGFR mutation is a strong predictor of efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) therapy in advanced non-small cell lung cancer (NSCLC). However, around 20–30 % of EGFR-mutated cases showed no response to EG
Autor:
Shuhang Wang, Jun Zhao, Ning-Hong Liu, Hua Bai, Xin Wang, Jie Wang, Xuyi Liu, Minglei Zhuo, Jianchun Duan, Meina Wu, Sonya Wei Song, Qingzhi Guo, Lu Yang, Yan Zhang, Yuyan Wang, Tongtong An
Publikováno v:
Lung Cancer. 67:343-347
The study aimed to investigate associations of tumor tissue EGFR mutations with response to the front-line chemotherapy and prognosis in advanced non-small cell lung cancer (NSCLC) patients. EGFR genotypes of 145 chemotherapy-naive patients with Stag